Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models

Angiogenesis

Volumn 16, Issue 2, 2013, Pages 429-441

  Eichten, Alexandra ^a   Adler, Alexander P ^a   Cooper, Blerta ^a   Griffith, Jennifer ^a   Wei, Yi ^a   Yancopoulos, George D ^a   Lin, Hsin Chieh ^a   Thurston, Gavin ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Preclinical model; Response biomarker; Tumor growth response; Tumor perfusion; VEGF blockade

Indexed keywords

AFLIBERCEPT; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; FIBROSARCOMA; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; MALE; MICROMORPHOLOGY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR BLOOD FLOW; TUMOR VOLUME;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS; POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 84879506911     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9328-3     Document Type: Article

References (53)

1. Ferrara N (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20(4):158-163. doi: 10.1684/ecn.2009.0170
2. Duda DG, Batchelor TT, Willett CG, Jain RK (2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 13(6):223-230. doi: 10.1016/j.molmed.2007.04.001 (Pubitemid 46836870)
3. Grepin R, Pages G (2010) Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010:835680. doi: 10.1155/2010/835680
4. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24. doi: 10.1200/JCO.2005.02.2574 (Pubitemid 46630489)
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134. doi: 10.1056/NEJMoa060655 (Pubitemid 46089673)
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390. doi: 10.1056/ NEJMoa0708857
7. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165(1):35-52 (Pubitemid 38821812)
8. Benjamin LE, Keshet E (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 94(16):8761-8766 (Pubitemid 27335113)
9. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145-147 (Pubitemid 38524883)
10. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58-62 (Pubitemid 40093472)
11. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13(13):3942-3950. doi: 10.1158/1078-0432.CCR-07-0278 (Pubitemid 47037602)
12. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88(12):1979-1986. doi: 10.1038/sj.bjc.6601005 (Pubitemid 36829677)
13. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS (2006) Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66(7):3639-3648. doi: 10.1158/0008-5472.CAN-05-3295
14. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, Smit EF (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21(1):82-91. doi: 10.1016/j.ccr.2011.11.023
15. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, Dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA (2012) Effects of Anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 11(3):752-762. doi: 10.1158/1535-7163.MCT-11-0742-T
16. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817-2823. doi: 10.1200/JCO.2009.26.3988
17. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104(47):18363-18370. doi: 10.1073/pnas.0708865104 (Pubitemid 350210713)
18. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444(7122):1032-1037. doi: 10.1038/nature05355 (Pubitemid 46018516)
19. Eichten A, Hyun WC, Coussens LM (2007) Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. Cancer Res 67(11):5211-5220 (Pubitemid 46997259)
20. Ho M, Yang E, Matcuk G, Deng D, Sampas N, Tsalenko A, Tabibiazar R, Zhang Y, Chen M, Talbi S, Ho YD, Wang J, Tsao PS, Ben-Dor A, Yakhini Z, Bruhn L, Quertermous T (2003) Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol Genomics 13(3):249-262. doi: 10.1152/physiolgenomics.00186.2002 (Pubitemid 37129190)
21. Rodewald HR, Sato TN (1996) Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cells. Oncogene 12(2):397-404 (Pubitemid 26042575)
22. de Fougerolles AR, Stacker SA, Schwarting R, Springer TA (1991) Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med 174(1):253-267
23. Woodfin A, Voisin MB, Nourshargh S (2007) PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 27(12):2514-2523. doi: 10.1161/ATVBAHA.107.151456 (Pubitemid 350158900)
24. Garlanda C, Dejana E (1997) Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol 17(7):1193-1202 (Pubitemid 27329839)
25. Gullino PM, Grantham FH (1961) Studies on the exchange of fluids between host and tumor. II. The blood flow of hepatomas and other tumors in rats and mice. J Natl Cancer Inst 27:1465-1491
26. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143(2):401-409 (Pubitemid 24058195)
27. de Jong D, Boot H, Taal B (2000) Histological grading with clinical relevance in gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Recent Results Cancer Res 156:27-32
28. Borre M, Offersen BV, Nerstrom B, Overgaard J (1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78(7):940-944 (Pubitemid 28430025)
29. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94(12):883-893 (Pubitemid 34778087)
30. Shin JW, Huggenberger R, Detmar M (2008) Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 112(6):2318-2326. doi: 10.1182/blood-2008-05-156331
31. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, Westholm JO, Komorowski J, Lassalle P, Cross MJ, Gerwins P (2007) Endocan is a VEGF-A and PI3 K regulated gene with increased expression in human renal cancer. Exp Cell Res 313(7):1285-1294. doi: 10.1016/j.yexcr.2007.01.021 (Pubitemid 46509777)
32. Su SC, Mendoza EA, Kwak HI, Bayless KJ (2008) Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in wound healing. Am J Physiol Cell Physiol 295(5):C1215-C1229. doi: 10.1152/ajpcell.00336.2008 (Pubitemid 352790352)
33. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444(7122):1083-1087. doi: 10.1038/nature05313 (Pubitemid 46018529)
34. Trotter MJ, Chaplin DJ, Durand RE, Olive PL (1989) The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 16(4):931-934 (Pubitemid 19154275)
35. Fenton BM, Paoni SF (2007) The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 67(20):9921-9928. doi: 10.1158/0008-5472.CAN-07-1066 (Pubitemid 47621241)
36. Eichten A, Shen H-CJ, Coussens LM (2005) Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy. In: Robinson JP (ed) Current protocols in cytometry, vol Suppl. 32. John Wiley & Sons, Inc, New Jersey, pp 12.15.11-12.15.11
37. Sahagun G, Moore SA, Fabry Z, Schelper RL, Hart MN (1989) Purification of murine endothelial cell cultures by flow cytometry using fluorescein-labeled griffonia simplicifolia agglutinin. Am J Pathol 134(6):1227-1232 (Pubitemid 19206309)
38. Chaplin DJ, Olive PL, Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 47(2):597-601 (Pubitemid 17009632)
39. Yopp AC, Schwartz LH, Kemeny NE, Gultekin D, Gonen M, Bamboat Z, Shia J, D'Angelica MI, DeMatteo RP, Jarnagin WR (2010) Dynamic contrast enhanced MRI (DCE-MRI) to measure antiangiogenic therapy and predict treatment response in primary liver cancer (PLC). J Clin Oncol (ASCO meeting abstract) 28 (suppl; abstr e14537)
40. Desjardins A, Barboriak DP, Herndon JE, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Friedman HS, Vredenburgh JJ (2007) Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). J Clin Oncol. ASCO Annual Meeting Proceedings Part I 25 (18S)
41. Checkley D, Tessier JJ, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC (2003) Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signaling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging 21(5):475-482 (Pubitemid 36899079)
42. Morgan B, Horsfield MA, Stattaus J, Khalil A, Gauler TC, Gounant V, Fischer B, Laurent D, Krissel H, Eberhardt WE (2007) Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 (PTK/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J Clin Oncol. ASCO Annual Meeting Proceedings Part I 25 (18S)
43. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13):5296-5300. doi: 10.1158/0008-5472.CAN-09-0814
44. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2):402-407. doi: 10.1158/0008-5472.CAN-11-2464
45. Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 16(4):1216-1225. doi: 10.1158/1078-0432.CCR-09- 2175
46. Lassau N, Chami L, Koscielny S, Chebil M, Massard C, Benatsou B, Bidault S, Cioffi A, Blay JY, Le Cesne A (2010) Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs. doi: 10.1007/s10637-010-9592-2
47. Lassau N, Chebil M, Chami L, Bidault S, Girard E, Roche A (2010) Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target Oncol 5(1):53-58. doi: 10.1007/s11523-010- 0136-7
48. Greis C (2009) Ultrasound contrast agents as markers of vascularity and microcirculation. Clin Hemorheol Microcirc 43(1):1-9. doi: 10.3233/CH-2009-1216
49. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C (2009) Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 72(3):217-238. doi: 10.1016/j.critrevonc.2008.07.012
50. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 66(3):1434-1445. doi: 10.1158/0008-5472.CAN-05-0923 (Pubitemid 43259924)
51. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27(18):3020-3026. doi: 10.1200/JCO.2008.21.1771
52. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23(31):8136-8139. doi: 10.1200/JCO.2005.02.5635 (Pubitemid 46657433)
53. Otrock ZK, Hatoum HA, Musallam KM, Awada AH, Shamseddine AI (2011) Is VEGF a predictive biomarker to anti-angiogenic therapy? Crit Rev Oncol Hematol 79(2):103-111. doi: 10.1016/j.critrevonc.2010.07.008